AP301 not checked
Alebund Pharmaceuticals · VS-505
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Three times a day, administered orally with three meals at a daily dose level from 0.075g to 0.25g”In the company’s words, NCT06933472 on ClinicalTrials.gov
- Tested for
- Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
- Main trialPhase 3
- “The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels? * Does AP301 works on serum calcium level, calcium times phosphate level, and intact parathyroid hormone level? * What discomfort or medical problem do the patients have when taking AP301? * Does AP301 improve quality of life in Chinese patients? The researchers will compare AP301 to an ineffective comparator (a look-alike substance that contains low dose AP301) to…”In the company’s words, NCT06933472 on ClinicalTrials.gov
- Other names
- VS-505
Other drugs for Hyperphosphatemia
- AP306R1 Therapeutics · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 20 Jun 2026 | A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China | |
| Phase 3Completed | 2 Oct 2024 | AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia | |
| Phase 2Completed | 30 Jun 2022 | A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients | |
| Phase 1Completed | 8 Feb 2024 | A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026